ClinicalTrials.gov
public full text
Public Domain
Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer
This phase I trial studies the side effects and best dose of bexarotene in preventing breast cancer in patients at high risk for breast cancer. Bexarotene belongs to a class of drugs that are called rexinoids, and it may reduce the incidence of breast tumors.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- ENCOrafenib With Binimetinib in bRAF NSCLC#1089107
- Brachytherapy in Treating Patients With Prostate Cancer#835041
- Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer#861926
- A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT#890204
- Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors#874659
Record · ID 1127546
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive